3 Absurdly Cheap Dividend Stocks to Buy in April 2026

AbbVie yields ~3.4% with a forward P/E of 14; market cap ~ $370B, trailing revenue $61.2B and operating margin ~33%, supporting its dividend record. Novo Nordisk yields ~4.9% with a forward P/E of 11 and ~41% operating margin, but expects revenue down as much as 13% this year and shares are down ~28% YTD. Verizon yields ~5.8% (payout ratio ~50%) with a forward P/E of 10; shares are up ~20% YTD in 2026 (down ~18% over five years) after stronger wireless growth and better-than-expected guidance.

Analysis

AbbVie's headline weakness masks an accounting and integration timing story that should mean normalized EPS and FCF flow through over a 6–18 month window; that normalization is the lever that converts a dividend play into a total-return opportunity as buyback cadence and M&A optionality become credible. Second-order: sustained cash generation makes AbbVie an activitist-friendly asset — expect either incremental buybacks or portfolio pruning (non-core divestitures) within the next 12 months, which would be a higher-velocity catalyst than organic revenue growth.

Novo Nordisk's price/volume reset is creating a market of lower near-term revenue expectations but structurally larger chronic-care TAM exposure, shifting bargaining power toward payers and PBMs; that pressure compresses gross margins but also forces the company into defensive pricing and expanded indications, which supports long-term stickiness of users. The key risk is competitive product launches that steal volume in the next 2–4 quarters; absent that, the current re-rating looks like a multi-quarter overshoot rather than a permanent impairment of the franchise.

Verizon’s improvement in subscriber metrics is a classic operational inflection that can drive margin re-leveraging if churn stabilizes and ARPU mix slowly recovers; this frees up capital for both fiber capex and shareholder distributions. However, telecom capex cycles and spectrum investment create sequencing risk — a one-quarter miss in broadband rollouts or ARPU can trigger sideways price action even if fundamentals remain intact.

Portfolio implication: the market is rotating into income anchors, compressing yields and creating crowding in defensive telecom/healthcare. That makes asymmetric option-structured exposures more attractive than naked long equity here — capture carry while keeping convex downside protection tied to specific catalysts (earnings normalizations, payer negotiations, fiber rollout milestones).

Key Decisions for Investors

• ABBV: Go long 12–24 months (target 2–4% portfolio). Hedge with a 12-month 15% OTM put or a put spread (buy 15% OTM put / sell 30% OTM put) to cap downside; expected return if earnings normalise and buybacks accelerate: ~10–20% total return, downside limited to put spread cost.
• VZ: Buy-write (buy stock / sell 6–9 month OTM calls) sized to 3% portfolio to harvest elevated carry while retaining modest upside to catalyst-driven rerating; if wireless metrics continue to improve, risk/reward is asymmetric (carry >3–4% in 6–9 months plus 8–12% upside), but be prepared to unwind on any broadband rollout miss.
• NVO: Small contrarian long with protection — buy stock sized to 1–2% portfolio and fund cost with a 9–12 month call sale (collar) or purchase a 9–12 month 20–30% OTM put spread; trade targets reacceleration or payer-coverage updates as exit signals. Position aims for 2:1 upside/downside if a volume recovery narrative reasserts within 12 months.
• Relative pair (tactical, 6–18 months): Long ABBV / short NVO sized dollar-neutral (each 1–2% portfolio) to express earnings-normalization vs. pricing-pressured volume risk. This reduces market beta and targets a spread capture if AbbVie’s one-offs fade while Novo’s volume recovery stalls.